Common Childhood Virus Linked to Alzheimer's Development in Old Age
Meet the Experts: David Hunter, M.D., an assistant professor and neurologist with UTHealth Houston, Linda Yancey, M.D., an infectious disease doctor at Memorial Hermann Health System; and Mark Santos, Ph.D., an assistant professor of microbiology and immunology at Touro University Nevada.
Study co-author Ruth Itzhaki, Ph.D., summarized her team's findings in a recent article for The Conversation and noted that, over the years, additional work has surfaced to support hers.
But what does it all mean, exactly? If a cold sore pops up, should you be concerned about dementia? We reached out to experts who explained everything.
'HSV-1 is a common virus to which almost everyone is exposed early in life,' says David Hunter, M.D., an assistant professor and neurologist with UTHealth Houston. 'It is best known for causing cold sores and is closely related to chicken pox and mononucleosis.'
What these viruses have in common is that they are neurotropic, meaning they linger in the nervous system long after the initial illness, explains Linda Yancey, M.D., an infectious disease doctor at Memorial Hermann Health System, and can be reactivated by stress or lowered immunity. That's how, for instance, chicken pox can manifest later in life as shingles, adds Dr. Hunter.
The virus's ability to infiltrate the nerves is believed to get it past the blood-brain barrier, a membrane that shields the organ from infection via the bloodstream. Thanks to that entry point, Dr. Hunter says, HSV-1 is the most common cause of viral brain inflammation in the United States.
'There is no vaccine for HSV and almost everyone will get it by adulthood,' Dr. Hunter adds. Cold sores are a mild case of it, and symptoms can be treated with antiviral drugs.
Dormant HSV-1 may be reactivated by illness and reach the brain, explains Mark Santos, Ph.D., an assistant professor of microbiology and immunology at Touro University Nevada. This can trigger brain inflammation over time, known as herpes encephalitis,and in people with genetic risk factors, like the ApoE-4 gene, contribute to Alzheimer's development, he adds. 'We don't entirely know why ApoE-4 is a risk factor for Alzheimer's,' adds Dr. Hunter. 'The link to HSV could be that ApoE-4 impacts the blood-brain barrier and makes it easier for HSV to enter.' And the inflammation caused by that entry may heighten Alzheimer's risk. 'It is now universally accepted that inflammation in the brain is a key step in the development of Alzheimer's,' Dr. Hunter reiterates.
In the three decades since the original study, doctors and researchers have learned much more about Alzheimer's disease and its connection to viral inflammation. For instance, several studies have found that being immunized for any disease (like COVID-19 or the flu) reduces Alzheimer's risk, says Dr. Hunter. 'Several other studies have shown that reducing inflammation in the brain helps prevent Alzheimer's,' he adds.
Santos concurs. 'Since 1996, additional studies have found HSV-1 DNA in the brains of individuals with Alzheimer's. Lab studies have also shown that HSV-1 infection can trigger the buildup of amyloid-beta and tau—proteins strongly associated with Alzheimer's pathology,' he explains.
However, there are a few disclaimers to note. Firstly, the posed risk is associated with people who contract HSV-1 in early life, giving it time to progressively cause inflammation. The risk may be lower in adults, says Santos. 'That said, if someone has other risk factors (like a weakened immune system or APOE-e4), adult-onset HSV-1 could still have long-term consequences,' he adds.
Still, neurotropic viruses are extremely common, Dr. Yancey reiterates. 'This makes it difficult to tease out whether they are causing neurologic problems or are simply common in the general population, including people with neurologic problems,' she adds. In other words, because most people end up with HSV-1 doesn't necessarily mean that most people will get Alzheimer's.
'Most cold sores aren't a cause for concern,' Santos adds. 'They're common and usually well-controlled by the immune system. But for people with frequent outbreaks, weakened immunity, or APOE-e4, it may be worth discussing with a healthcare provider. The concern is not a single cold sore, but long-term viral activity in the brain.'
More research, including long-term studies, is needed to make any solid associations, Santos and Dr. Yancey conclude. 'The current data is based on population-level surveys. There is no way to predict on an individual patient's level whether this has a meaningful impact,' says Dr. Yancey.
Future research will, hopefully, at least help experts understand how antiviral treatment affects Alzheimer's risk, as well as identify better ways to detect when HSV-1 is active in the brain. 'The hope is that understanding how infections contribute to Alzheimer's will open up new ways to prevent or treat it—especially before symptoms start,' says Santos.
Being vaccinated, exercising, engaging in mental stimulation, and maintaining a heart-healthy diet are all known ways to lower dementia risk, our experts say. Avoiding smoking or nicotine use of any kind can also 'drastically' reduce the risk, says Dr. Yancey. All of these habits and choices work together to support both immune and brain health.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Hengrui and Kailera report positive data from Phase III obesity treatment trial
Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former's Phase III trial (HRS9531-301) of subcutaneous injections of HRS9531 once per week in those with obesity or who are overweight in China. The HRS9531-301 study targeted adults with obesity or who were overweight and had a minimum of one weight-related comorbidity, excluding those with diabetes. Subjects were randomly assigned and given HRS9531 at doses of 2mg, 4mg, 6mg, or a placebo for a 48-week period. Out of the 567 enrolees, 531 completed the study. The double-blind, randomised, placebo-controlled multi-centre trial has met its primary endpoints. Participants who received the dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist, HRS9531, at these doses experienced significantly more weight loss than those who took a placebo during the 48-week timeframe. The 567 individuals in the trial had a mean baseline body weight of 93kg. The primary analysis showed that those treated with HRS9531 achieved a mean weight loss of up to 17.7%, with the placebo-adjusted figure being 16.3%. In addition, the trial showed that up to 88% of those treated with HRS9531 lost at least 5% of their body weight, and 44.4% achieved a weight reduction of at least 20%. A pre-specified supplementary analysis showed a mean weight loss of up to 19.2%, with a placebo-adjusted figure of 17.7%. The safety profile of HRS9531 was favourable, aligning with GLP-1-based therapies and consistent with previous Phase II clinical data. Hengrui is now preparing to submit a new drug application in China for chronic weight management while Kailera is set to expand the therapy, as KAI-9531, into worldwide trials. Kailera Therapeutics CEO and president Ron Renaud said: 'We commend our colleagues at Hengrui for these impressive Phase III clinical results, building on the strong momentum behind HRS9531 (KAI-9531). 'As Kailera prepares to advance KAI-9531 into a global clinical programme, we look forward to evaluating both higher doses and longer duration of treatment to expand on KAI-9531's best-in-class potential.' HRS9531 is under development to treat type 2 diabetes and conditions related to obesity. Earlier this year, both companies reported encouraging topline data from a Phase II obesity trial involving an 8mg dose of HRS9531. "Hengrui and Kailera report positive data from Phase III obesity treatment trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
27 minutes ago
- Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. 167% increase in GLP-1 production and a 358% increase in PYY production (a satiety-induced hormone produced in the intestine). Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased's efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased's patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily intake of spermidine. Spermidine is associated with benefits to longevity, cardiovascular health and brain health. The paper states that 'during (Almased's) proteolytic enzyme procedure, bioactive and biogenic peptides, which were not detectable before in the raw materials, naturally occur. It can be assumed that the production process is significant in producing bioactive compounds responsible for unexpected positive effects on the metabolism, even in people who are not overweight'. Other key findings in the 2022 review in Heliyon have shown: 167% increase in GLP-1 production and a 358% increase in PYY production (a satiety-induced hormone produced in the intestine) compared to consuming a standard American diet containing the same amount of calories by the same individuals (Oliveira et al. 2022) Almased group lost 145% more weight than the control group (-13lbs vs. -5.3lbs) in 12 weeks. Fat loss was 181% more in the Almased group (-9.9 lbs) than in the control group (-3.52 lbs) over the same period of time despite comparable weights before the study (Röhling et al. 2020) Almased plus resistance training increased muscle strength by 33% versus resistance training alone (Deibert et al 2010) Waist circumference reduction 239% greater in the Almased group compared to a fat-reduced diet (2.4in vs. 0.7in) after 6 weeks. Fat mass loss was 82% greater in the Almased group compared to a fat-reduced diet (11.2lbs vs. 6.1lbs) after 6 weeks (König et al 2008) A study on post-menopausal women saw a 62% reduction in the prevalence of metabolic syndrome and significant fat loss without losing lean mass (Deibert et al. 2007) Almased reduced liver fat content by an average of 56% and supports a healthy inflammatory response (Deibert et al 2019) Almased preserved 100% muscle mass while losing weight (Deibert et al 2004) Researchers found that Almased improves the fat burning process so you burn fat and calories more effectively (Oliveira et al 2021). In overweight and obese individuals, Almased meal replacement regimens resulted in greater reductions in body weight, body mass index (BMI), and fat mass compared to traditional low-calorie diets, while also improving glycemic control and lipid profiles. Beyond weight management, the review highlights Almased's role in supporting healthy blood sugar levels in both prediabetic and type 2 diabetic individuals. This indicates Almased is safe for people with diabetes. The review also notes Almased's unique anti-aging and wellness benefits. Regular use has been linked to healthy cell function, reduced stress markers, and better overall energy and mood. Almased's protein-rich formula, containing essential amino acids and bioactive peptides, supports muscle preservation, cellular health, and supports a healthy inflammatory response, contributing to improved quality of life and longevity. 'The results presented underscore the efficacy of the soy-yogurt-honey formula (Almased) in weight management and the improvement of obesity-associated cardiovascular disease and metabolic risk factors.' said the study's authors. About Almased Founded over 30 years ago in Germany by holistic therapist Hubertus Trouillé, and his son Andre Trouillé, Almased is a family-owned and operated company dedicated to promoting health and wellness worldwide. Recognized as Europe's #1 science backed weight-loss meal replacement shake brand, Almased combines natural ingredients with a patented fermentation process to deliver high-quality, effective nutrition. With over 30 peer reviewed studies across 3 decades, Almased is a global leader in metabolic health. With a commitment to sourcing the highest quality ingredients in the world, Almased continues its mission to help people achieve healthier, happier lives with clean, sustainable products.


Business Wire
an hour ago
- Business Wire
Genascence Announces U.S. Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to GNSC-001 for Knee Osteoarthritis (OA)
PALO ALTO, Calif.--(BUSINESS WIRE)--Genascence Corporation ('Genascence'), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA). GNSC-001 is a genetic medicine – a recombinant adeno-associated viral vector expressing an optimized human interleukin-1 receptor antagonist (IL-1Ra), a naturally occurring protein that blocks IL-1 signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single intra-articular injection into the affected joint. 'GNSC-001 is the first IL-1 inhibitor for OA that has been shown to generate IL-1Ra expression levels that maintain therapeutic thresholds long-term following a single administration to inhibit pathogenic IL-1. The FDA RMAT designation for GNSC-001 underscores the strength of the clinical data to date, recognizing its potential to transform the treatment paradigm for OA,' said Thomas Chalberg, Ph.D., founder and CEO of Genascence. 'With the RMAT designation for GNSC-001, we look forward to working closely with the FDA as we seek to accelerate late-stage clinical development of GNSC-001 so we can bring a new treatment option to people suffering from this incapacitating, disabling disease.' To date, GNSC-001 has been studied in two human clinical trials. The first-in-human Phase 1 study (NCT02790723) was a single-center, open-label, dose-escalation design in nine participants with knee OA. The DONATELLO Phase 1b clinical trial (NCT05835895) is a double-blind, placebo-controlled dose-ranging study designed to evaluate the safety, tolerability, and pharmacodynamics of a single intra-articular injection of GNSC-001 in patients with OA of the knee that enrolled 67 participants at 10 centers across the U.S. The RMAT designation is a special FDA program aimed at speeding up the development and review of promising cell and gene therapies under the 21 st Century Cures Act. The FDA grants RMAT designation to drug candidates that show potential to treat, modify, reverse, or cure serious or life-threatening diseases and address unmet medical needs. The FDA's RMAT designation offers sponsor companies all the benefits of the fast track and breakthrough therapy designation programs. In addition, RMAT designation provides accelerated development and review pathways for regenerative medicine products, including early and intensive FDA guidance, potential eligibility for accelerated approval and priority review, and the possibility of rolling review. The U.S. Food and Drug Administration (FDA) granted GNSC-001 Fast Track designation in the fourth quarter of 2024. Earlier this year, Genascence completed a successful meeting with the FDA on the design of the Phase 2b/3 clinical trial of GNSC-001 focused on clinical efficacy and plans to initiate the Phase 2b/3 study in 2026. The DONATELLO clinical trial was supported by a $12 million award from the California Institute for Regenerative Medicine (CLIN2-14265). About Osteoarthritis (OA) of the Knee Osteoarthritis (OA) is a progressive joint disease that is a leading cause of disability. It is characterized by destruction of cartilage and structural changes in bone within the joint, which contribute to pain and loss of joint function. Osteoarthritis affects more than 30 million Americans and is increasing as a result of the aging population and increasing prevalence of obesity. Osteoarthritis represents a major economic burden, owing to direct medical costs and loss of productivity. Each year, millions of patients are treated for knee OA with NSAIDs, opioids, and steroid injections into the knee to manage their knee pain. There are no currently available therapies known to alter or slow down OA progression. About Genascence Corporation Genascence, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, is developing life-changing treatments for highly prevalent conditions affecting millions of people. The company was founded in 2017 with technology licensed from three leading U.S. research institutions: Mayo Clinic, University of Florida, and NYU Langone Health. Headquartered in Palo Alto, California, Genascence's founders and leadership team have deep experience in the design, development, and manufacturing of successful gene therapies and biological medicines. For more information, please visit